Geoffrey McDonough appointed President and CEO of Swedish Orphan Biovitrum

27-Jun-2011 - Sweden

Geoffrey McDonough has been appointed President and CEO of Swedish Orphan Biovitrum AB (Sobi) as of August 15, 2011. He will succeed Kennet Rooth, who has been acting CEO since January 1, 2011.

Geoffrey McDonough is currently President of Europe, Middle East, and Africa (EMEA) of Genzyme Corporation, USA, one of the world's leading biotechnology companies, now part of the French Sanofi Group. In this role Dr. McDonough is responsible for operations in 55 countries and a portfolio of 15 leading biotechnology and specialty products. Dr. McDonough has held several leading positions within Genzyme in the US since 2002, including Senior VP and General Manager, Personalized Genetic Health, and Senior VP, Global Business Unit Leader, LSD (Lysosomal Storage Diseases) Therapeutics. Dr. McDonough began his career at Genzyme in Corporate Development. Prior to joining Genzyme Dr. McDonough worked as a physician in the US, and also has had experience as a medical technology entrepreneur and as an adviser for RA Capital Management in the US.

Geoffrey McDonough was born in 1970 and is a graduate of Harvard Medical School. He holds a Bachelor of Arts and a Bachelor of Science from University of North Carolina, where he was awarded the highest honor for his Bachelor's thesis.

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...